Defective Drug Attorney Serving Dallas-Fort Worth, TX
Reclast Risks Require New Labeling by the FDA
Due to several reported cases of renal failure, the U.S. Food and Drug Administration has decided to approve an update to the drug label for Reclast (zoledronic acid).
What is Reclast?
Reclast is a type of drug called bisphosphonate that is given to men and postmenopausal women to treat and prevent osteoporosis. It is also given to patients who are suffering from Paget’s disease. Reclast is meant to prevent osteoclasts from destroying bone and to promote steady bone growth. Reclast is administered by an intravenous infusion once every 1-2 years.
Unfortunately, many of those who take Reclast are unaware of the risks and dangers, and those taking the drug or considering taking Reclast should discuss risk factors with their physician. Risk factors include such things as previous kidney failure, taking non-steroidal anti-inflammatory drugs, advanced age, and diuretic therapy.
Note: Hydration is imperative before and after the administration of Reclast because dehydration may increase the risk of renal failure.
What are the Symptoms of Renal (Kidney) Failure?
There may be no symptoms with the onset of kidney failure. This is why your doctor may order a blood test called serum creatinine level before and after each dose of Reclast. This blood test is used to determine how well your kidneys are functioning in response to the medication. Symptoms typically begin appearing as kidney function decreases due inability to promote red blood cell production, regulate water and electrolyte balances, and clear waste products from the body.
These symptoms include:
- Generalized swelling
- Shortness of breath
If left untreated, these may turn into more life-threatening symptoms such as:
- Heart rhythm disturbances
- Decreased muscle function
- Inflammation of heart lining
- Decrease in mental function and/or coma
- Congestive heart failure